Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Technical Assessment of an Automated Treatment Planning on Dose Escalation of Pancreas Stereotactic Body Radiotherapy.

Wang S, Zheng D, Lin C, Lei Y, Verma V, Smith A, Ma R, Enke CA, Zhou S.

Technol Cancer Res Treat. 2019 Jan 1;18:1533033819851520. doi: 10.1177/1533033819851520.

2.

Can the Student Outperform the Master? A Plan Comparison Between Pinnacle Auto-Planning and Eclipse knowledge-Based RapidPlan Following a Prostate-Bed Plan Competition.

Smith A, Granatowicz A, Stoltenberg C, Wang S, Liang X, Enke CA, Wahl AO, Zhou S, Zheng D.

Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819851763. doi: 10.1177/1533033819851763.

3.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
4.

Times Not to Forget Radiotherapy When Treating Patients With Lymphoma.

Enke CA.

J Oncol Pract. 2019 Apr;15(4):167-172. doi: 10.1200/JOP.18.00519.

PMID:
30970228
5.

Automatic planning on hippocampal avoidance whole-brain radiotherapy.

Wang S, Zheng D, Zhang C, Ma R, Bennion NR, Lei Y, Zhu X, Enke CA, Zhou S.

Med Dosim. 2017 Spring;42(1):63-68. doi: 10.1016/j.meddos.2016.12.002.

PMID:
28237294
6.

Prostate bed target interfractional motion using RTOG consensus definitions and daily CT on rails : Does target motion differ between superior and inferior portions of the clinical target volume?

Verma V, Chen S, Zhou S, Enke CA, Wahl AO.

Strahlenther Onkol. 2017 Jan;193(1):38-45. doi: 10.1007/s00066-016-1077-6. Epub 2016 Dec 1.

PMID:
27909738
7.

RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.

Hein AL, Post CM, Sheinin YM, Lakshmanan I, Natarajan A, Enke CA, Batra SK, Ouellette MM, Yan Y.

Oncogene. 2016 Dec 8;35(49):6319-6329. doi: 10.1038/onc.2016.163. Epub 2016 May 16.

8.

Prostate Cancer, Version 1.2016.

Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.

PMID:
26733552
9.

Technical Note: Fabricating Cerrobend grids with 3D printing for spatially modulated radiation therapy: A feasibility study.

Zhu X, Driewer J, Li S, Verma V, Lei Y, Zhang M, Zhang Q, Zheng D, Cullip T, Chang SX, Wang AZ, Zhou S, Enke CA.

Med Phys. 2015 Nov;42(11):6269-73. doi: 10.1118/1.4932223.

PMID:
26520719
10.

Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation.

Yan Y, Hein AL, Etekpo A, Burchett KM, Lin C, Enke CA, Batra SK, Cowan KH, Ouellette MM.

Oncotarget. 2014 Nov 15;5(21):10251-70.

11.

Preclinical evaluation of investigational radiopharmaceutical RISAD-P intended for use as a diagnostic and molecular radiotherapy agent for prostate cancer.

Kortylewicz ZP, Mack E, Enke CA, Estes KA, Mosley RL, Baranowska-Kortylewicz J.

Prostate. 2015 Jan;75(1):8-22. doi: 10.1002/pros.22885. Epub 2014 Oct 4.

PMID:
25283970
12.

Prostate cancer, version 2.2014.

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 May;12(5):686-718.

PMID:
24812137
13.

Prostate cancer, version 1.2014.

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2013 Dec 1;11(12):1471-9.

PMID:
24335682
14.

A nonhuman primate model of human radiation-induced venocclusive liver disease and hepatocyte injury.

Yannam GR, Han B, Setoyama K, Yamamoto T, Ito R, Brooks JM, Guzman-Lepe J, Galambos C, Fong JV, Deutsch M, Quader MA, Yamanouchi K, Kabarriti R, Mehta K, Soto-Gutierrez A, Roy-Chowdhury J, Locker J, Abe M, Enke CA, Baranowska-Kortylewicz J, Solberg TD, Guha C, Fox IJ.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):404-411. doi: 10.1016/j.ijrobp.2013.10.037. Epub 2013 Dec 5.

15.

Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens.

Hemstreet GP 3rd, Rossi GR, Pisarev VM, Enke CA, Helfner L, Hauke RJ, Tennant L, Ramsey WJ, Vahanian NN, Link CJ.

J Immunother. 2013 Jan;36(1):57-65. doi: 10.1097/CJI.0b013e3182780abc.

PMID:
23211622
16.

Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA.

J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7.

PMID:
22956807
17.

Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group.

Lin C, Donaldson SS, Meza JL, Anderson JR, Lyden ER, Brown CK, Morano K, Laurie F, Arndt CA, Enke CA, Breneman JC.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1764-70. doi: 10.1016/j.ijrobp.2011.01.036. Epub 2011 Apr 4.

18.

Radiation for diffuse large B-cell lymphoma: more questions than answers.

Bierman PJ, Enke CA.

Oncology (Williston Park). 2010 Nov 30;24(13):1213-4. No abstract available.

19.

Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer.

Abe M, Kortylewicz ZP, Enke CA, Mack E, Baranowska-Kortylewicz J.

Cancers (Basel). 2011 May 25;3(2):2501-15. doi: 10.3390/cancers3022501.

20.

New options in diagnosis and management of mycosis fungoides and Sézary syndrome.

Enke CA.

Oncology (Williston Park). 2010 May;24(6):507-8. No abstract available.

21.

Comparison of transabdominal ultrasound and electromagnetic transponders for prostate localization.

Foster RD, Solberg TD, Li HS, Kerkhoff A, Enke CA, Willoughby TR, Kupelian PA.

J Appl Clin Med Phys. 2010 Jan 6;11(1):2924.

22.

NCCN clinical practice guidelines in oncology: prostate cancer.

Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC.

J Natl Compr Canc Netw. 2010 Feb;8(2):162-200. No abstract available.

PMID:
20141676
23.

Temporal and regional variations in the use of preoperative radiation therapy for rectal cancer.

Lin C, Charlton ME, Meza JL, Enke CA, Loberiza FR Jr.

Am J Clin Oncol. 2010 Oct;33(5):443-7. doi: 10.1097/COC.0b013e3181b4b175.

PMID:
19952718
24.

Dosimetric consequences of intrafraction prostate motion.

Li HS, Chetty IJ, Enke CA, Foster RD, Willoughby TR, Kupellian PA, Solberg TD.

Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):801-12. doi: 10.1016/j.ijrobp.2007.10.049. Epub 2008 Jan 30.

PMID:
18234439
25.

Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer.

Baranowska-Kortylewicz J, Abe M, Nearman J, Enke CA.

Clin Cancer Res. 2007 Jan 1;13(1):299-306.

26.

Comparison of Kodak EDR2 and Gafchromic EBT film for intensity-modulated radiation therapy dose distribution verification.

Sankar A, Ayyangar KM, Nehru RM, Kurup PG, Murali V, Enke CA, Velmurugan J.

Med Dosim. 2006 Winter;31(4):273-82.

PMID:
17134667
27.

Ultrasound-based guidance of intensity-modulated radiation therapy.

Fung AY, Ayyangar KM, Djajaputra D, Nehru RM, Enke CA.

Med Dosim. 2006 Spring;31(1):20-9. Review.

PMID:
16551526
28.

Effects of field parameters on IMRT plan quality for gynecological cancer: a case study.

Fung AY, Enke CA, Ayyangar KM, Thompson RB, Zhen W, Raman NV, Djajaputra D, Li S, Nehru RM, Pillai S, Sourivong P, Headley M, Yager AL.

J Appl Clin Med Phys. 2005 Summer;6(3):46-62. Epub 2005 Aug 12.

29.

Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.

Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kurizaki T, Nearman J, Paulsson J, Mosley RL, Enke CA, Ostman A.

Cancer Res. 2005 Sep 1;65(17):7824-31.

30.

Anal canal cancer clinical practice guidelines in oncology.

Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jul;3(4):510-5. No abstract available.

PMID:
16038641
31.

Rectal cancer clinical practice guidelines in oncology.

Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jul;3(4):492-508. No abstract available.

PMID:
16038640
32.

Colon cancer clinical practice guidelines in oncology.

Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jul;3(4):468-91. No abstract available.

PMID:
16038639
33.

Dose volume histogram comparison between ADAC Pinnacle and Nomos Corvus systems for IMRT.

Ayyangar KM, Fung AY, Li S, Pillai S, Yoe-Sein MM, Zhen W, Enke CA.

Australas Phys Eng Sci Med. 2005 Mar;28(1):1-7.

PMID:
15920983
34.

Cell-phone interference with pocket dosimeters.

Djajaputra D, Nehru R, Bruch PM, Ayyangar KM, Raman NV, Enke CA.

Phys Med Biol. 2005 May 7;50(9):N93-9. Epub 2005 Apr 13.

PMID:
15843727
35.

Follicular lymphoma: expanding therapeutic options.

Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO.

Oncology (Williston Park). 2005 Feb;19(2):213-28; discussion 228, 233-6, 239. Review.

36.

Prostate motion and isocenter adjustment from ultrasound-based localization during delivery of radiation therapy.

Fung AY, Enke CA, Ayyangar KM, Raman NV, Zhen W, Thompson RB, Li S, Nehru RM, Pillai S.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):984-92.

PMID:
15752877
37.

Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptides.

Kurizaki T, Abe M, Sanderson SD, Enke CA, Baranowska-Kortylewicz J.

Mol Cancer Ther. 2004 Jan;3(1):85-91.

38.

Radiolabeled constructs for evaluation of the asialoglycoprotein receptor status and hepatic functional reserves.

Abe M, Lai J, Kortylewicz ZP, Nagata H, Fox IJ, Enke CA, Baranowska-Kortylewicz J.

Bioconjug Chem. 2003 Sep-Oct;14(5):997-1006.

PMID:
13129404
39.
40.

Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a.

Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J.

J Nucl Med. 2002 Jul;43(7):957-67.

41.

Clinical aspects of IMRT--part III.

Saw CB, Zhen W, Ayyangar KM, Enke CA.

Med Dosim. 2002 Summer;27(2):75-7. No abstract available.

PMID:
12074471
42.

Clinical implementation of intensity-modulated radiation therapy.

Saw CB, Ayyangar KM, Zhen W, Yoe-Sein M, Pillai S, Enke CA.

Med Dosim. 2002 Summer;27(2):161-9. Review.

PMID:
12074468
43.

Intensity-modulated radiation therapy (IMRT): the radiation oncologist's perspective.

Zhen W, Thompson RB, Enke CA.

Med Dosim. 2002 Summer;27(2):155-9.

PMID:
12074467
44.

Leaf sequencing techniques for MLC-based IMRT.

Saw CB, Siochi RA, Ayyangar KM, Zhen W, Enke CA.

Med Dosim. 2001 Summer;26(2):199-204.

PMID:
11444522
45.

Independent dose calculations for the corvus MLC IMRT.

Ayyangar KM, Nizin PS, Saw CB, Gearheart D, Shen B, Enke CA.

Med Dosim. 2001 Summer;26(2):135-41.

PMID:
11444515
46.

Commissioning and quality assurance for MLC-based IMRT.

Saw CB, Ayyangar KM, Zhen W, Thompson RB, Enke CA.

Med Dosim. 2001 Summer;26(2):125-33.

PMID:
11444514
47.

MLC-based IMRT-Part II.

Saw CB, Ayyangar KM, Enke CA.

Med Dosim. 2001 Summer;26(2):111-2. No abstract available.

PMID:
11444512
48.

Quality assurance procedures for the Peacock system.

Saw CB, Ayyangar KM, Zhen W, Thompson RB, Enke CA.

Med Dosim. 2001 Spring;26(1):83-90.

PMID:
11417512
49.

Immobilization devices for intensity-modulated radiation therapy (IMRT).

Saw CB, Yakoob R, Enke CA, Lau TP, Ayyangar KM.

Med Dosim. 2001 Spring;26(1):71-7.

PMID:
11417510
50.

Commissioning of Peacock System for intensity-modulated radiation therapy.

Saw CB, Ayyangar KM, Thompson RB, Zhen W, Enke CA.

Med Dosim. 2001 Spring;26(1):55-64.

PMID:
11417508

Supplemental Content

Support Center